🇺🇸 FDA
Pipeline program

Neratinib

3144A1-2206 / B1891017

Phase 3 small_molecule active

Quick answer

Neratinib for Breast Cancer is a Phase 3 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 8 ClinicalTrials.gov record(s).

Program details

Company
PUMA BIOTECHNOLOGY, INC.
Indication
Breast Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials